Pooled TETON trials show inhaled treprostinil slows FVC decline in IPF

Combined results from the TETON-1 and TETON-2 phase 3 trials in 1191 patients with idiopathic pulmonary fibrosis found that inhaled treprostinil reduced the decline in forced vital capacity at 52 weeks compared with placebo (median change -45.4 mL vs -161.7 mL, between-group difference 111.8 mL, p<0.0001). The trials reported treprostinil was superior to placebo on five of six secondary endpoints, including time to clinical worsening, time to IPF exacerbation, quality of life (K-BILD), and percent predicted DLCO, with fewer deaths in the treprostinil group (6.9% vs 9.4%); cough was the most common adverse event.

Most relevant for: Patients with idiopathic pulmonary fibrosis being considered for or managed with inhaled prostacyclin therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.